Pierre Fustier

1.1k total citations
23 papers, 392 citations indexed

About

Pierre Fustier is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Pierre Fustier has authored 23 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in Pierre Fustier's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and CAR-T cell therapy research (4 papers). Pierre Fustier is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and CAR-T cell therapy research (4 papers). Pierre Fustier collaborates with scholars based in Switzerland, United States and France. Pierre Fustier's co-authors include Dominique Bernard-Gallon, Ludovic Le Corre, Nasséra Chalabi, Yves‐Jean Bignon, János G. Filep, Shao‐Ling Zhang, Julie R. Ingelfinger, Tusty‐Jiuan Hsieh, John S.D. Chan and I. George Fantus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Pierre Fustier

22 papers receiving 379 citations

Peers

Countries citing papers authored by Pierre Fustier

Since Specialization

Citations

This map shows the geographic impact of Pierre Fustier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Fustier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Fustier more than expected).

Fields of papers citing papers by Pierre Fustier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Fustier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Fustier. The network helps show where Pierre Fustier may publish in the future.

Co-authorship network of co-authors of Pierre Fustier

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Fustier. A scholar is included among the top collaborators of Pierre Fustier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Fustier. Pierre Fustier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study 2023 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), Christof Zitt, (unknown), (unknown), (unknown), Pierre Fustier, Vaia Stavropoulou, (unknown), (unknown), Kate E. Watkins, (unknown), (unknown), Philippe Legenne, Michael T. Stumpp, Malcolm Boyce	3
2	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma 2019 ·International Journal of Hematology ·Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo, Go Yamamoto, Takayuki Ishikawa, Tsutomu Kobayashi, Toru Kiguchi, Hirokazu Nagai, Tomoko Ohtsu, Stacey Kalambakas, Pierre Fustier, (unknown), Kensei Tobinai	5
3	AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R²) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS 2019 ·Hematological Oncology ·John P. Leonard, Marek Trněný, Koji Izutsu, Nathan Fowler, Xin Hong, (unknown), Fritz Offner, Adriana Scheliga, Grzegorz S. Nowakowski, Antonio Pinto, Francesca Re, Laura Maria Fogliatto, Phillip Scheinberg, Ian W. Flinn, (unknown), M. S. Czuczman, Stacey Kalambakas, Pierre Fustier, Chengqing Wu, JG Gribben	8
4	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) 2019 ·Blood ·Marek Trněný, John P. Leonard, Huilai Zhang, Grzegorz S. Nowakowski, Koji Izutsu, Nathan Fowler, Catherine Thiéblemont, Pier Luigi Zinzani, Stacey Kalambakas, Myron S. Czuczman, Pierre Fustier, Chengqing Wu, John G. Gribben	1
5	Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma. 2017 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Nagesh Kalakonda, Lorenz Truemper, Hele Everaus, Pierre Fustier, Jonathan Jaeger, Oliver Manzke, Ulrich Jäger, (unknown)	2
6	AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R²) versus placebo plus rituximab. 2015 ·Journal of Clinical Oncology ·John P. Leonard, John G. Gribben, Marek Trněný, Phillip Scheinberg, Kensei Tobinai, Nathan Fowler, Nurgul Kilavuz, Pierre Fustier, (unknown), (unknown)	1
7	Insulin, CCAAT/Enhancer-Binding Proteins and Lactate Regulate the Human 11β-Hydroxysteroid Dehydrogenase Type 2 Gene Expression in Colon Cancer Cell Lines 2014 ·PLoS ONE ·(unknown), Pierre Fustier, (unknown), (unknown), (unknown), Felix J. Frey, Brigitte M. Frey	7
8	Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08) 2012 ·Clinical Lung Cancer ·Martin Früh, Richard Cathomas, Marco Siano, (unknown), Alfred Zippelius, Christoph Mamot, Andreas Erdmann, (unknown), Daniel Rauch, Mathew Simcock, (unknown), Pierre Fustier, Miklos Pless	22
9	Identification of polymorphisms in the human 11beta‐hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity 2007 ·The FASEB Journal ·(unknown), Fatemeh Fouladkou, Pierre Fustier, Bruno Cenni, Arya M. Sharma, Hans‐Christian Deter, Brigitte M. Frey, Felix J. Frey	41
10	Extracellular ATP Determines 11β-Hydroxysteroid Dehydrogenase Type 2 Activity via Purinergic Receptors 2005 ·Journal of the American Society of Nephrology ·Bert Kadereit, Pierre Fustier, (unknown), Brigitte M. Frey, Felix J. Frey, Markus G. Mohaupt	9
11	Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines 2004 ·Clinica Chimica Acta ·Ludovic Le Corre, Pierre Fustier, Nasséra Chalabi, Yves‐Jean Bignon, Dominique Bernard-Gallon	40
12	Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells 2004 ·Journal of Endocrinology ·Tusty‐Jiuan Hsieh, Pierre Fustier, Chih‐Chang Wei, Shao‐Ling Zhang, János G. Filep, (unknown), Julie R. Ingelfinger, I. George Fantus, Pavel Hamet, John S.D. Chan	38
13	Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines 2003 ·British Journal of Cancer ·Pierre Fustier, Ludovic Le Corre, Nasséra Chalabi, (unknown), Yves Communal, Y. J. Bignon, Dominique Bernard-Gallon	42
14	High Glucose Stimulates Angiotensinogen Gene Expression and Cell Hypertrophy via Activation of the Hexosamine Biosynthesis Pathway in Rat Kidney Proximal Tubular Cells 2003 ·Endocrinology ·Tusty‐Jiuan Hsieh, Pierre Fustier, Shao‐Ling Zhang, János G. Filep, Shiow‐Shih Tang, Julie R. Ingelfinger, I. George Fantus, Pavel Hamet, John S.D. Chan	78
15	Differential effects of <I>n</I>-3 and <I>n</I>-6 polyunsaturated fatty acids on <I>BRCA1</I> and <I>BRCA2</I> gene expression in breast cell lines 2002 ·British Journal Of Nutrition ·Dominique Bernard-Gallon, (unknown), (unknown), Pascale Rio, (unknown), Pierre Fustier, (unknown)	39
16	Presence of BRCA1 and BRCA2 proteins in human milk fat globules after delivery 2002 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·(unknown), D. Lémery, Ludovic Le Corre, Pierre Fustier, Pierre Déchelotte, Jean‐Claude Maurizis, Yves–Jean Bignon, Dominique Bernard-Gallon	16
17	Differential effects ofn-3 andn-6 polyunsaturated fatty acids onBRCA1andBRCA2gene expression in breast cell lines 2002 ·British Journal Of Nutrition ·Dominique Bernard-Gallon, (unknown), (unknown), Pascale Rio, Jean‐Claude Maurizis, Pierre Fustier, Yves‐Jean Bignon	32
18	Préparation et circulation du bronze dans la Gaule préromaine 1960 ·Gallia préhistoire ·Pierre Fustier	1
19	Notes sur la constitution des voies romaines en Italie. 1960 ·Revue des Études Anciennes ·Pierre Fustier	2
20	Notes sur la constitution des voies romaines en Italie. 1958 ·Revue des Études Anciennes ·Pierre Fustier	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact